×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ATRA – atara biotherapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ATRA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/30
08:52 am
atra
Atara Biotherapeutics: An Empty Pipeline With Little Gas [Seeking Alpha]
High
Report
Atara Biotherapeutics: An Empty Pipeline With Little Gas [Seeking Alpha]
11/14
01:10 pm
atra
Atara Biotherapeutics (NASDAQ:ATRA) had its "sell (d+)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Atara Biotherapeutics (NASDAQ:ATRA) had its "sell (d+)" rating reaffirmed by analysts at Weiss Ratings.
11/12
09:17 am
atra
Atara Biotherapeutics: Q3 Earnings Snapshot [Yahoo! Finance]
Low
Report
Atara Biotherapeutics: Q3 Earnings Snapshot [Yahoo! Finance]
11/12
09:00 am
atra
Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress
Low
Report
Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress
11/9
01:10 am
atra
Atara Biotherapeutics (NASDAQ:ATRA) was downgraded by analysts at Weiss Ratings from a "hold (c-)" rating to a "sell (d+)" rating.
Low
Report
Atara Biotherapeutics (NASDAQ:ATRA) was downgraded by analysts at Weiss Ratings from a "hold (c-)" rating to a "sell (d+)" rating.
11/3
09:00 am
atra
Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
Medium
Report
Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
10/24
12:16 pm
atra
Atara Biotherapeutics (NASDAQ:ATRA) was upgraded by analysts at Weiss Ratings from a "sell (d+)" rating to a "hold (c-)" rating.
Low
Report
Atara Biotherapeutics (NASDAQ:ATRA) was upgraded by analysts at Weiss Ratings from a "sell (d+)" rating to a "hold (c-)" rating.
10/3
03:30 pm
atra
Atara Biotherapeutics (NASDAQ:ATRA) had its "sell (d+)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Atara Biotherapeutics (NASDAQ:ATRA) had its "sell (d+)" rating reaffirmed by analysts at Weiss Ratings.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/1
05:00 pm
atra
Form 4 Atara Biotherapeutics, For: Nov 28 Filed by: Huang James
High
Report
Form 4 Atara Biotherapeutics, For: Nov 28 Filed by: Huang James
11/19
04:55 pm
atra
Form 4 Atara Biotherapeutics, For: Nov 17 Filed by: Nguyen AnhCo
Medium
Report
Form 4 Atara Biotherapeutics, For: Nov 17 Filed by: Nguyen AnhCo
11/19
04:55 pm
atra
Form 4 Atara Biotherapeutics, For: Nov 17 Filed by: Grant-Huerta Yanina
Medium
Report
Form 4 Atara Biotherapeutics, For: Nov 17 Filed by: Grant-Huerta Yanina
11/17
05:52 pm
atra
Form 144 Atara Biotherapeutics, Filed by: Nguyen AnhCo
Low
Report
Form 144 Atara Biotherapeutics, Filed by: Nguyen AnhCo
11/17
05:50 pm
atra
Form 144 Atara Biotherapeutics, Filed by: Grant-Huerta Yanina
Low
Report
Form 144 Atara Biotherapeutics, Filed by: Grant-Huerta Yanina
11/14
04:26 pm
atra
Form SCHEDULE 13D/A Atara Biotherapeutics, Filed by: Redmile Group, LLC
Medium
Report
Form SCHEDULE 13D/A Atara Biotherapeutics, Filed by: Redmile Group, LLC
11/14
04:08 pm
atra
Form SCHEDULE 13G/A Atara Biotherapeutics, Filed by: EcoR1 Capital, LLC
Medium
Report
Form SCHEDULE 13G/A Atara Biotherapeutics, Filed by: EcoR1 Capital, LLC
11/12
09:11 am
atra
Form 10-Q Atara Biotherapeutics, For: Sep 30
Low
Report
Form 10-Q Atara Biotherapeutics, For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/19
Atara Biotherapeutics Inc (NASDAQ: ATRA) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating.
25.1%
11/7 Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress 11.2%
2/5 Atara Biotherapeutics Names Kristin Yarema as Chief Commercial Officer 8.5%
8/9 Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 6.1%
9/10 Atara Biotherapeutics Inc (NASDAQ: ATRA) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 6.0%
2/27 Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.8%
3/3 Form 4 Atara Biotherapeutics, For: Mar 01 Filed by: Touchon Pascal 5.8%
7/18 Form 424B5 Atara Biotherapeutics, 5.7%
4/22 Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) 5.7%
12/11 Atara Biotherapeutics Inc (NASDAQ: ATRA) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 5.5%
11/7 Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress 11.2%
2/5 Atara Biotherapeutics Names Kristin Yarema as Chief Commercial Officer 8.5%
8/9 Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 6.1%
9/10 Atara Biotherapeutics Inc (NASDAQ: ATRA) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 6.0%
2/27 Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.8%
3/3 Form 4 Atara Biotherapeutics, For: Mar 01 Filed by: Touchon Pascal 5.8%
7/18 Form 424B5 Atara Biotherapeutics, 5.7%
4/22 Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) 5.7%
12/11 Atara Biotherapeutics Inc (NASDAQ: ATRA) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 5.5%
TOP News Decliners
5/9
Q1/2019 3/31/2019 EPS -1.440 ZacksConsensus -1.480 ActVsEst 0.040 - Beat
-20.6%
7/16 Atara Biotherapeutics Announces Plan to Initiate Tab-cel® FDA Biologics License Application Submission Next Year -11.9%
2/21 Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) -10.3%
5/12 Atara Biotherapeutics, Inc. 2019 Q1 - Results - Earnings Call Slides [Seeking Alpha] -8.6%
2/19 Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020 -8.4%
10/29 Atara Biotherapeutics Inc (NASDAQ: ATRA) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.7%
5/7 Atara Biotherapeutics Inc (NASDAQ: ATRA) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -7.7%
7/16 Atara Biotherapeutics Inc (NASDAQ: ATRA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.3%
6/29 Atara Biotherapeutics Presents Initial ATA188 Phase 1 Safety Results for Patients with Progressive Multiple Sclerosis at the 5th Congress of the European Academy of Neurology (EAN) -7.2%
8/1 Atara Biotherapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 8, 2019 -7.1%
7/16 Atara Biotherapeutics Announces Plan to Initiate Tab-cel® FDA Biologics License Application Submission Next Year -11.9%
2/21 Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) -10.3%
5/12 Atara Biotherapeutics, Inc. 2019 Q1 - Results - Earnings Call Slides [Seeking Alpha] -8.6%
2/19 Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020 -8.4%
10/29 Atara Biotherapeutics Inc (NASDAQ: ATRA) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.7%
5/7 Atara Biotherapeutics Inc (NASDAQ: ATRA) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -7.7%
7/16 Atara Biotherapeutics Inc (NASDAQ: ATRA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.3%
6/29 Atara Biotherapeutics Presents Initial ATA188 Phase 1 Safety Results for Patients with Progressive Multiple Sclerosis at the 5th Congress of the European Academy of Neurology (EAN) -7.2%
8/1 Atara Biotherapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 8, 2019 -7.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: